Martin Greg
Division of Pulmonary, Allergy and Critical Care, Emory University School of Medicine, Atlanta, Georgia, USA.
Crit Care. 2005;9(6):649-50. doi: 10.1186/cc3931. Epub 2005 Nov 22.
Albumin is a frequently prescribed drug in hospitalized patients, and its effect on clinical outcomes has been scrutinized in recent years. Data from meta-analyses has suggested harm related to albumin therapy in critically ill patients, and new observational data are consistent with these results. However, appropriately powered randomized, controlled trials have shown albumin to be safe in broad groups of critically ill patients. This article will discuss the reasons for differences between observational and controlled trial data, and the implications for future albumin use and clinical research.
白蛋白是住院患者常用的处方药，近年来其对临床结局的影响受到了仔细审查。荟萃分析的数据表明，白蛋白治疗对重症患者有危害，新的观察性数据也与这些结果一致。然而，有充分统计学效力的随机对照试验表明，白蛋白在广大重症患者群体中是安全的。本文将讨论观察性数据与对照试验数据存在差异的原因，以及对未来白蛋白使用和临床研究的影响。
